The marijuana company would work with Novartis' generic drug business Sandoz, and supply non-smokable and non-combustible medical cannabis products where it is legally allowed. » Read More
Attorney Mark Lanier, who won a nearly $4.7 billion J&J talc verdict, says the recent stock plunge plays into his hands in seeking a settlement. » Read More
By: Elizabeth Gurdus
Jim Cramer reveals why Johnson & Johnson could hold the key to this market's ability to turn around. » Read More
By: Elizabeth Gurdus
Jim Cramer sits down with Johnson & Johnson Chairman and CEO Alex Gorsky to address reports of his company knowing that its talc-based baby powder contained traces of asbestos. » Read More
Johnson & Johnson plans to repurchase $5 billion in shares after the company lost more than $50 billion in market value over two trading days following a scathing news report Friday claiming J&J knew its talc baby powders contained asbestos.
Investors sold off shares of Johnson & Johnson on Friday after a Reuters report said the company knew for decades that its baby powder contained asbestos, an allegation J&J has denied.
Endo International shares slid 8 percent as a '60 Minutes' report on data collected by opioid distributors regarding the amounts and destinations of painkillers is set to air Sunday.
Jim Cramer uses the tech sector to make a case for picking individual stocks over risky exchange-traded funds.
J.P. Morgan downgrades Pfizer shares to neutral from overweight, warning clients that the stock's 2018 run up will likely slow.
Jim Cramer reveals a play that could be worth considering despite the recent volatility.
Jim Cramer says there's more to Wall Street newcomer Moderna than the action in the biotechnology company's stock.
The deal represents a more than 60 percent premium to Tesaro's closing price on Friday of $46.38 per share.
This week the Trump administration proposed allowing Medicare Part D pharmacy drug plans to be more selective on branded drugs from what are known as the six special therapeutic classes, which include cancer treatments and H-I-V antiviral drugs.
The Centers for Medicare and Medicaid Services proposed changes to Medicare prescription drug coverage that would allow insurers to stop covering certain "protected" classes of drugs used to treat common ailments like depression, cancer and HIV.
Novartis CEO Vas Narasimhan says there is a fundamental challenge with pricing new cell and gene therapies that are potentially curative: how to pay for these therapies and make them available to patients in need.
In modernizing the 510(k) approval process, the FDA wants medical device manufacturers to base new products on devices that are no older than 10 years old. Currently, companies can compare new devices to technology that's about 40 years old.
Sales of edibles, vape pens and other marijuana gifts spiked on the Wednesday before Thanksgiving last year and as retailers increasingly promote it as an unofficial shopping holiday ahead of Black Friday, Small Business Saturday and Cyber Monday.
The Florida lawsuit accuses the drug stores and pharmaceutical distributors of playing as big a role in the proliferation of opioid addiction as the drug manufacturers of OxyContin and fentanyl, a synthetic opioid 50 times stronger than heroin.
Pfizer deferred planned drug price increases this summer after President Donald Trump criticized the drug giant on Twitter.
BioMarin's clinical trial of a gene therapy for hemophilia is providing hope to patients with the disease. It is an experimental treatment that uses a virus to deliver a healthy copy of a gene to make up for one that causes excessive bleeding.